ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: John Campbell, Nida Contracts Chief, New Head Of NCI Contracts Branch; PHS Honors Seven At NCI

June 10, 1983

ACCC Seeks Expanded Backing For CHOP, Other Community Cancer Programs

November 7, 1980

Control AC Hear Report On High Risk conference, Messer Survey

September 6, 1974

Memorial’s Scher Warns FDA About Flaws In Provenge Data, Urges Not To Approve.

April 13, 2007

NIH Revitalization Act Authorizes $3 Billion For NCI In FY97

July 5, 1996

OSCC Groups Send Four Concepts To NCI Board

September 13, 1985